Context In the management of urothelial carcinoma, determination of the pathological grade
aims at stratifying tumours into different prognostic groups to allow evaluation of treatment …

Stage T1 bladder cancers invade the lamina propria of the bladder and, despite sharing
many of the genetic features of muscle-invasive bladder cancers, are classified as non …

Stage T1 bladder cancers have the highest progression and recurrence rates of all non–
muscle-invasive bladder cancers (NMIBCs). Most T1 cancers are treated with bacillus …

Abstract Context Bacillus Calmette-Guérin (BCG) is currently the most effective intravesical
therapy for nonmuscle invasive bladder cancer, reducing not only recurrence rates but also …

Bladder cancer is a heterogeneous disease that is not depicted by current classification
systems. It was originally classified into non-muscle invasive and muscle invasive. However …

Precision medicine has transformed the way urothelial carcinoma is managed. However,
current practices are limited by the availability of tissue samples for genomic profiling and …

Abstract High-grade T1 (HGT1) bladder cancer is the highest risk subtype of non–muscle-
invasive bladder cancer with unpredictable outcome and poorly understood risk factors …

With the mechanistic understanding of immune checkpoints and success in checkpoint
blockade using antibodies for the treatment of certain cancers, immunotherapy has become …

Abstract Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment
failure, suggesting that patients could benefit from a more personalized treatment approach …

Background With advancements in molecular biology techniques, great progress has been
made in the understanding of urothelial carcinoma pathogenesis. Objective To examine the …